TY - JOUR T1 - Use of ceftazidime in the treatment of otorhinolaryngoiatric bacterial infections. AU - Vellucci,A, AU - Marcucci,L, AU - Greco,D, AU - Schinaia,N, AU - Caterini,A, AU - Benedetti,M, PY - 1987/5/1/pubmed PY - 1987/5/1/medline PY - 1987/5/1/entrez SP - 282 EP - 8 JF - International journal of clinical pharmacology, therapy, and toxicology JO - Int J Clin Pharmacol Ther Toxicol VL - 25 IS - 5 N2 - Within the framework of an investigation into otorhinolaryngoiatric bacterial infections in Italy conducted in 1159 patients (607 with otitis media, 354 with pharyngo-tonsillitis and 198 with sinusitis), 124 ceftazidime-treated subjects (92 with otitis media, 22 with pharyngo-tonsillitis and 10 with sinusitis) were observed. The authors report the examination of a number of microbial isolates obtained in the various forms of otorhinolaryngoiatric bacterial infection. Gram-negative organisms were found as causative agents in such diseases, particularly in otitis media. Bacterial resistance to ceftazidime was assessed in all 1159 cases and proved relatively infrequent (3.6%) and markedly less than the detected resistance to other antibiotics (10.7% resistance to cefotaxime, 35% resistance to ampicillin, 43% resistance to penicillin). Ceftazidime, used mainly in otitis media, showed very substantial clinical efficacy with positive results in as many as 97% of cases treated, which is particularly significant, if one considers that roughly 64% of the infections were caused by "difficult" gram-negative bacteria (49% by Pseudomonas). SN - 0174-4879 UR - https://www.unboundmedicine.com/medline/citation/3298082/Use_of_ceftazidime_in_the_treatment_of_otorhinolaryngoiatric_bacterial_infections_ DB - PRIME DP - Unbound Medicine ER -